Eli Lilly Raises Revenue Outlook After Record Q3
The pharmaceutical giant credits soaring weight-loss drug sales and new Medicare coverage for its updated 2026 forecast.
Updated on Oct. 29, 2026 in Healthcare
Live Poll
Do you trust that major pharmaceutical companies prioritize patient health over maximizing their own corporate profits?
Eli Lilly has increased its annual revenue outlook for 2026 to between $91 billion and $92 billion following record third-quarter results. The company reported total quarterly sales of $24.4 billion, driven by massive demand for its weight-loss treatments.
Why it matters
Growth is largely fueled by the July expansion of Medicare coverage for weight-loss drugs, which significantly increased access for older adults. Zepbound sales exceeded both internal company targets and analyst expectations, cementing the firm's dominance in the market.
Eli Lilly recorded $5.4 billion in Zepbound revenue for the third quarter, while its weight-loss drug portfolio now accounts for 66% of total revenue. The company also absorbed a $4.2 billion charge related to the acquisitions of AtaiBeckley and Curevo.
The players
Eli Lilly
This American pharmaceutical company is a major developer and manufacturer of medications for obesity, diabetes, and other chronic conditions.
The details
Total quarterly net income reached $6.5 billion as the manufacturer continues to scale production to serve the growing patient population. Medicare coverage for GLP-1 drugs is expected to generate an additional $4 billion in revenue for the firm by the end of 2026.
Timeline
July 1, 2026: Medicare officially began covering weight-loss drugs.
Q3 2026: Quarterly sales figures were finalized.
October 22, 2026: Company stock reached an all-time high of $1,306.69.
October 29, 2026: Article published regarding stock movement and revenue updates.
End of 2026: Projected total revenue gain from Medicare expansion.
Market Landscape
This performance highlights the impact of the Medicare weight-loss drug coverage expansion on the broader pharmaceutical sector. The move establishes a significant new revenue stream that positions the company ahead of competitors struggling to scale similar treatments.
The expansion of Medicare coverage provides older adults with broader access to GLP-1 weight-loss prescriptions. Patients should contact their healthcare providers to determine if their current coverage plans reflect these recent changes in pharmaceutical eligibility.
The takeaway
The sharp increase in demand underscores how policy changes in government-funded programs can immediately reshape commercial profitability for drug manufacturers. Consumers should monitor updates from both their medical providers and insurance carriers as access parameters for new weight-loss medications continue to evolve.
Further reading
For more on industry performance, see the Healthcare sector analysis.
Live Poll
Do you trust that major pharmaceutical companies prioritize patient health over maximizing their own corporate profits?
